Oral Iron Substitution for Orthopedic Surgery

Iron Deficiency Anemia Clinical Trial

Official title:

Pilot Study for Investigation of the Feasibility and for Optimization of Oral Iron Substitution in the Course of Patient Blood Management for Orthopedic Surgery

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02973074
• Other study ID #: C-124-16
• Status: Terminated
• Phase: N/A
• Start date: November 25, 2016
• Est. completion date: November 1, 2017

Study information

• Verified date: August 2018
• Source: Kepler University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this pilot study is to investigate an 4 weeks period of oral iron substitution in the course of Patient Blood Management in preparation for orthopedic surgery.

Description:

Patient blood management (PBM) is a clinical multidisciplinary, patient orientated concept for treatment of anaemia, reduction of intraoperative blood loss and increasing anaemic tolerance.

In the Kepler University Hospital (former General Hospital Linz) PBM was introduced in 2006. Since then patients for elective orthopedic surgery (knee an hip replacement) are screened for iron deficiency anaemia and if needed treated with the more effective intravenous iron.

Oral iron medications are not as efficient (low bioavailability, more side effects) as the intravenous iron infusion. Although there is risk of anaphylactoid reactions.

In this study the new oral iron supplement OLEOvital Eisen forte (available in Austria) ist tested on its effectivity for treatment of iron deficiency in the course of PBM.

It has a much more higher bioavailability without the typically side effects of the routinely used oral iron medications.

Within this study the investigators want to examine the feasibility of this iron substitution concept OLEOvital and its efficacy. Also the investigators want to get pilot data for a further randomized controlled trial.

The increase of the hemoglobin level in 4 weeks of minimum 1g/dl is going to be expected and monitored.

For comparison of the new oral substitution concept OLEOvital with the standard intravenous iron substitution an historic control group is going to be used.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: November 1, 2017
• Est. primary completion date: November 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• age over 55 years

• indication for patient blood management for elective orthopedic surgery

• listed for a orthopedic surgery (e.g. hip or knee replacement) 5-7 weeks after begin of patient blood management

• Haemoglobin male < 12-13g/dl, female <11-12g/dl

• written informed consent after written and verbal information

Exclusion Criteria:

• indication for treatment with erythropoietin

• pregnancy

• nursing period

• diarrhea or tendency to diarrhea

• fructose intolerance

• pre - menopause

• permanent or expected blood loss

• participation in other study

• expected compliance problems

• legal incapacity

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Iron Deficiency Anemia

Intervention

Dietary Supplement:
• OLEOvital
2sachets with 30mg iron per day for a 4 weeks period

Locations

Country	Name	City	State
Austria	Kepler University Hospital	Linz

Sponsors (1)

Lead Sponsor	Collaborator
Kepler University Hospital

Country where clinical trial is conducted

Austria, 

References & Publications (4)

Danninger T, Rasul R, Poeran J, Stundner O, Mazumdar M, Fleischut PM, Poultsides L, Memtsoudis SG. Blood transfusions in total hip and knee arthroplasty: an analysis of outcomes. ScientificWorldJournal. 2014 Jan 21;2014:623460. doi: 10.1155/2014/623460. eCollection 2014. — View Citation

Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion. 2007 Aug;47(8):1468-80. — View Citation

Meybohm P, Richards T, Isbister J, Hofmann A, Shander A, Goodnough LT, Muñoz M, Gombotz H, Weber CF, Choorapoikayil S, Spahn DR, Zacharowski K. Patient Blood Management Bundles to Facilitate Implementation. Transfus Med Rev. 2017 Jan;31(1):62-71. doi: 10.1016/j.tmrv.2016.05.012. Epub 2016 May 28. Review. — View Citation

Seicean A, Alan N, Seicean S, Neuhauser D, Weil RJ. The effect of blood transfusion on short-term, perioperative outcomes in elective spine surgery. J Clin Neurosci. 2014 Sep;21(9):1579-85. doi: 10.1016/j.jocn.2014.03.003. Epub 2014 May 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	increase of hemoglobin level		4 weeks